36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
3 citations
,
February 2013 in “PubMed” 5α-reductase inhibitors like finasteride and dutasteride can help treat skin disorders stimulated by androgens, such as hair loss and acne.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” 5ARI treatment improves hair growth in older men with minimal side effects.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
20 citations
,
May 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
83 citations
,
April 1992 in “Journal of Biological Chemistry” Four-amino acid part makes enzyme sensitive to finasteride.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
5 citations
,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
June 2024 in “Reviews on Recent Clinical Trials” Finasteride and dutasteride may cause metabolic issues like liver disease and diabetes.
4 citations
,
December 2019 in “Minerva Urology and Nephrology” 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.